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Outline
Pathophysiology of osteoporosis
 Nitric oxide and bone turnover
 The effects of isosorbide mononitrate on
markers of bone turnover
 The effects of nitroglycerin on bone
turnover geometry and strength


Effect of estrogen and transdermal
NTG on BMD (Wimalawansa et al Bone 1996)
Treatment group

Sham operated
Ovariectomized rats
Ovariectomized + Estrogen
Ovariectomized + NTG
Ovariectomized + E + NTG
*different than ovariectomized rats at p<0.005
** different than ovariectomized rats at p<0.02

Percent increase in
BMD (L2-L4) over 6
weeks
25% r 2%
8% r 3%
27% r 5%*
20% r 3%**
22% r 2%*

Low bone mineral density
(BMD): a risk factor for
osteoporotic fractures
Relationship between hip fracture and hip
BMD: 2.6 RR/SD
 BMD = bone formation - bone resorption
 Increased bone resorption at menopause
 Nitric oxide may contribute to
postmenopausal bone loss


Sources of nitric oxide
Exogenous
Isosorbide Mononitrate
Isosorbide Dinitrate
Nitroglycerin
L-arginine + O2

Nitric Oxide

Nitric Oxide
Synthase
(NOS)
Endogenous

Nitrate & Nitrite

Bone cells make nitric oxide
Two cell types involved in bone remodeling:
Osteoclasts o bone resorption
Osteoblasts o bone formation
 Osteoblasts produce enitric oxide synthase
 Estrogen and mechanical strain produce
initric oxide synthase


NO influences osteoclasts
 Nitric

oxide has a biphasic effect on
osteoclasts
Low levels enhance osteoclast activity
and differentiation
High levels inhibit osteoclast activity and
differentiation

NO may mediate effects via OPG
 High

levels of nitric oxide activate OPG
 Low levels of nitric oxide activate OPGL

Bone resorption depends on the
balance of OPG and OPGL
OPGL

BONE

OPG

The OPG/OPGL/RANK axis
Hormones OPG Ligand

RANK

OPG

Osteoclast
Precursor

OPG

Osteoblasts

RANK

NO
Osteoclast

Bone

What about osteoblasts?
 Limited

data
 Biphasic activity:
High levels of NO stimulate
osteoblast activity
Low levels of NO inhibit osteoblast
activity

In vitro data: a summary


Nitric oxide stimulates OPG
OPG binds to OPGL
Prevents binding of OPGL to RANK
Decreased osteoclast activity (bone
resorption)



Issues
Is the effect similar with nitric oxide donors?
Does the decrease in bone resorption lead to
increased bone mineral density?

Effect of estrogen and transdermal
NTG on BMD (Wimalawansa et al Bone 1996)
Treatment group

Sham operated
Ovariectomized rats
Ovariectomized + Estrogen
Ovariectomized + NTG
Ovariectomized + E + NTG
*different than ovariectomized rats at p<0.005
** different than ovariectomized rats at p<0.02

Percent increase in
BMD (L2-L4) over 6
weeks
25% r 2%
8% r 3%
27% r 5%*
20% r 3%**
22% r 2%*

Effect of frequency of administration
Treatment Group (n = 5)
Sham operated
Ovariectomy (OVX)

Change in Spine
BMD
6.3 % r 5.3 *
– 2.5 % r 2.0

OVX + estrogen

5.9 % r 3.4*

OVX + 0.2 mg NTG once a day

6.2 % r 2.8*

OVX + 0.2 mg NTG twice a day

1.9 % r 2.1

OVX + 0.2 mg NTG three times a day
Wimalawansa SJ et al. JBMR 2000

– 0.2 % r 3.3

Does NO play a role in menopause?
Menopause is characterized by:
Increased bone resorption
Low circulating estrogen
Low levels of nitric oxide
 Treatment with HRT increases nitric oxide
and decreases bone resorption


Nitrates and bone mineral density 1996


SOF study (n = 6201) (Jamal SA et al JBMR 1998)
BMD at heel and spine
 Daily

users = nonusers
 Intermittent users higher

Open label trial (n = 16) (Wimalawansa SJ, JBMR 2000).
 Conjugated estrogen or transdermal
nitroglycerin
 Equal BMD at one year


Percent difference in BMD, nitrate
users compared with nonusers
Daily vs.
Nonusers
(n = 317, 5810)
(95% CI)

Intermittent vs.
Nonusers
(n=74,5810)
(95% CI)

Hip BMD
Unadjusted
Adjusted

0 (-2.7 to 1.4)
1.3 (0.14 to 4.1)

0 (-4.1 to 4.1)
2.6 (0.4 to 6.8)

Heel BMD
Unadjusted
Adjusted

-2.6 (-5.3 to 0)
0 (-2.6 to 2.6)

0 (-5.3 to 7.9)
5.3 (2.6 to 11)
Jamal SA, et al. JBMR 1998

Nitrates and Fractures
124,655 subjects with fractures (cases)
 373,962 controls
 Self-reported nitrate use 1995-200
 Nitrate use associated with decreased
fracture risk:
Any fracture: OR = 0.89 (0.86 to 0.92)
Hip fracture: OR = 0. 85 (0.79 to 0.92)


Rejnmark L et al, JBMR 2006

Findings so far...
 Use

of nitrates may be associated
with increases in BMD
 Use of nitrates may decrease risk of
fractures
 Tolerance to nitrates might exist

The second study- 1998
 To

determine the effects of isosorbide
on markers of bone turnover
 To assess if there is a dose response
 Applied for funding 1998, received
funding 1999
 Completed study 2002
 Published 2004

Study design
Phase I

Phase II

Calcium 500 mg

Vitamin D 400 IU
ISMO 5 mg
or ISMO 20 mg
or Placebo
0

1

2

3
Months

Blood
Urine

4

5

6

Blood
Urine

Study subjects




Inclusion Criteria:
Postmenopausal women, 50 to 80 yrs
Osteopenia or normal BMD at femoral neck
Exclusion Criteria:
Low trauma fracture (hip, wrist, spine)
Active bone disease
Treatment for osteoporosis
Treatment with steroids
Heart disease

Markers of bone turnover
2

classes of biochemical markers:
Bone formation (osteoblast activity)
Bone resorption (osteoclast activity)
 Resorption and formation are
coupled
 May be different with ISMO

Why biochemical markers?
 Markers

of bone turnover are
correlated with bone mineral density
 Substantial changes in markers can
be seen within 3 months of treatment
 Minimizes costs
 Minimizes adverse events

451 women screened

206 ineligible

245 eligible

99 did not participate

146 women : calcium and vitamin D

2 did not return

144 women randomized

48 : placebo

49 : 5 mg ISMO

47 : 20 mg ISMO

4 drop outs
no samples

11 drop outs
6 samples

10 drop outs
5 samples

44 : placebo

44 : 5 mg ISMO

42 : 20 mg ISMO

Subject characteristics
Age (yrs)
Weight (kg)
Caucasian
Current smoker
Years since
menopause
NTX (nmol BCE/mmol
Cr
)
BSAP
(IU/L)

Placebo
(n = 48)
62 r 7.0
74 r 16
45 (94%)
5 (10%)

5 mg ISMO
(n = 49)
59 r 7.5
70 r 15
44 (90%)
5 (10%)

20 mg ISMO
(n = 47)

13 r 8

12 r 10

10 r 6

62 r 65.9

79 r 61.8

82 r 71.5

25 r 6.9

23 r 6.3

22 r 6.6

59 r 5.5
74 r 15

44 (94%)
7 (15%)

Jamal SA et al, JBMR 2004

ISMO decreased bone resorption
markers
40

NTX
Percent
change
vs.
placebo

20

p = 0.0002

p = 0.0001

0
-20
-40

-36.3

-60
5 mg

-45.4
20 mg

ISMO increased bone formation
markers
40

BSAP
Percent
change
vs.
placebo

15.9

23.3

20
0
-20

p = 0. 005

p = 0.001

-40
-60

5 mg

20 mg

Headaches were common
Placebo
(n = 48)

5 mg ISMO
(n = 49)

20 mg ISMO
(n = 47)

Discontinued study

4

11

10

D/C due to headache

2

7

9

Limitations
 Generalizability

Study population healthy Caucasians
 Duration

of study was 12 weeks
 Studies with BMD and fracture end
points are needed

Implications of our findings






Decrease in NTx similar to bisphosphonates
40% decrease in NTx: 30% decrease in fracture
risk
We also found an increase in formation markers?greater fracture reduction than with
antiresorptives
Headache may limit the use of this drug:
10% of women had headaches, 75% of drop outs
4X more common in women randomized to ISMO
Higher than reported in CV literature
?Less headaches with transdermal NTG

The third study








Applied for funding March 2004- rejected
Reapplied for funding March 2005
Funded October 2005
Completed Trial March 2010
2 part randomized controlled trial:
3 week cross over study to compare
tolerability of NTG and ISMO
2 year study of best tolerated nitrate
Outcomes in 2 year study:
Change in lumbar spine and hip BMD
Change in bone turnover markers
Changes in trabecular bone with pQCT

Study Hypothesis
15 mg of Nitroglycerin, applied once
daily, will lead to uncoupling of bone
turnover, increases in bone mineral
density and bone geometry, compared
with placebo.

Study Design
 One

week run in phase
 24 month duration
 End points:
Bone turnover markers
Bone mineral density
pQCT

Study Subjects
 Inclusion:

Postmenopausal  50 years
L spine T score between 0 and -2.0
 Exclusion:

Migraine headaches
Already taking nitrates
SBP  100 mm Hg, DBP 110 mm Hg

Statistical Analyses
 Primary

Endpoint:

Lumbar spine BMD
 Secondary

Endpoints:

Hip BMD
pQCT at radius and tibia
B-ALP, NTX (log transformed data)

Assessed for
eligibility (n=1526)

-

Excluded (n = 1283)
Did not meet inclusion criteria (541)
Declined to participate (585)

Enrolled in 1 week run in
phase (n = 400)

Discontinued study (n= 157)
Headaches (93)
Headaches and nausea (11)

Randomized (n = 243)
Nitroglycerin ( n =126)
-

Discontinued intervention ( n = 30)
Headaches ( n =7)
No follow up data ( n = 8)
Analysed:
Data on 116 at 24 m

Placebo ( n = 117)
L

-

Discontinued intervention ( n =15)
Headaches ( n = 2)
Lost to follow up ( n = 6)
Analysed:
Data on 109 at 24m

Age (yrs)
Weight (kg)
Vitamin D (IU/day)
Calcium (mg/day)
L Spine T-score

NTG
Ointment
N = 126

Placebo
N = 117

61.3
70.3
783. 2
1548.8
-0.9

61.9
70.9
753.2
1565.6
-1.1

Nitrate=126
Placebo=117

35.9%
(34.4 to 37.4)

6.7%
(5.2 to 8.2)

7.0%
(5.5-8.5)

6.2%
(5.2 to 7.3)

PQCT of the Radius
Measurement

% Difference (95%CI)

Trabecular density
Cortical thickness
Cortical density
Cortical area
Periosteal circumference

11.9 (8.1 to 15.7)
13.9 (6.0 to 21.7)
2.2 (0.6 to 3.7)
10.6 (6.9 to 14.3)
7.4 (4.3 to 10.4)

Indices of Radial Bone Strength
Measurement

% difference (95%CI)

Polar Section Modulus 10.7 (7.5 to 13.8)
Polar Moment of
Inertia

7.3 (4.6 to 10.1)

PQCT of the Tibia
Measurement

% Difference (95%CI)

Trabecular density
Cortical thickness
Cortical density
Cortical area
Periosteal circumference

8.5 (4.3 to 12.7)
24.6 (18.9 to 30.4)
1.5 (0.8 to 2.3)
10.0 (5.2 to 15.0)
2.9 (1.0 to 6.8)

Indices of Tibial Bone
Strength
Measurement

% difference (95%CI)

Polar Section Modulus 9.8 (0.2 to 19.4)
Polar Moment of
Inertia

14.5 (3.2 to 25.8)

Headaches
Run In
Phase

400 enrolled, 104 did not
continue

Treatment

Nitroglycerin

Placebo

d/c at 12
months

7 (23.3%)

2 (13.3%)

1 month

35%
5.3%
2%

5.4%
0.9%
0

12 months
24 months

Nitroglyceri Placebo
n
Serious Adverse events 5 (4.2%)
5 (4.3%)
-Death
Fractures

1 (1%)

0

2 (1.6%)

2 (1.7%)

Conclusions
 Nitroglycerin

uncouples bone turnover
 Improves BMD, geometry, indices of
strength
 Inexpensive and widely available
 Initiation of treatment limited by headache
 The efficacy of nitroglycerin to reduce
fracture risk should be tested in a clinical
trial

